ResearchWCN26-3077 PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF SEFAXERSEN IN CHINESE HEALTHY PARTICIPANTS: A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, PHASE 1 STUDY
ResearchWCN26-3501 EVALUATION OF PATHOPHYSIOLOGY BIOMARKERS IN KIDNEY BIOPSIES COLLECTED IN IMAgINATION, A PHASE 3 STUDY OF SEFAXERSEN IN PATIENTS WITH IgA NEPHROPATHY
ResearchWCN26-5317 POPULATION PK/PD MODELING TO ASSESS ETHNIC SENSITIVITY IN THE CLINICAL DEVELOPMENT OF SEFAXERSEN
Research#3089 Suppression of complement alternative pathway by monthly dosing of sefaxersen, a novel antisense oligonucleotide therapy in development for IgAN
ResearchWCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
ResearchNephrology Referral Based on Laboratory Values, Kidney Failure Risk, or Both: A Study Using Veterans Affairs Health System Data
ResearchOutcomes Among Patients With Left Ventricular Assist Devices Receiving Maintenance Outpatient Hemodialysis: A Case Series
ResearchNational Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race
ResearchThe effect of blood flow rate on dialysis recovery time in patients undergoing maintenance hemodialysis: A prospective, parallel-group, randomized controlled trial